The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 vector technology.

After treatment with CAR-T cells—immune cells engineered to attack cancer—patients sometimes tell their doctors they feel like they have “brain fog,” or forgetfulness and difficulty concentrating. A ...

Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few months.

The project could eventually add more than 400 manufacturing jobs and over 1,500 construction jobs during site development.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.